Liang M. Zhang

Franz Josef Strauß Allee 11
Regensburg, BY 93053, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

Diagnostic Value of Dynamic Contrast Enhanced Ultrasound (CEUS) with Time Intensity Curve (TIC) Analysis for Differentiating Musculoskeletal Benign and Malignant Soft Tissue Tumors.

Diagnostic Value of Dynamic Contrast Enhanced Ultrasound (CEUS) with Time Intensity Curve (TIC) Analysis for Differentiating Musculoskeletal Benign and Malignant Soft Tissue Tumors.

Journal: RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin

Published: August 26, 2026

Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial'.

Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial'.

Journal: ESMO open

Published: May 22, 2026

Genomic Catastrophe Defines the Evolutionary Trajectory of Adrenocortical Carcinoma.

Genomic Catastrophe Defines the Evolutionary Trajectory of Adrenocortical Carcinoma.

Journal: Endocrine pathology

Published: March 28, 2026

Stereotactic Microwave Ablation of Early-Stage Hepatocellular Carcinoma in Patients with Transjugular Intrahepatic Portosystemic Shunts: A Matched Case-Control Study.

Stereotactic Microwave Ablation of Early-Stage Hepatocellular Carcinoma in Patients with Transjugular Intrahepatic Portosystemic Shunts: A Matched Case-Control Study.

Journal: Cardiovascular and interventional radiology

Published: March 02, 2026

Network-based analysis reveals potential microRNA regulation of oncogenic pathways in SOX10-depleted uveal melanoma.

Network-based analysis reveals potential microRNA regulation of oncogenic pathways in SOX10-depleted uveal melanoma.

Journal: Cellular and molecular life sciences : CMLS

Published: December 23, 2025

Safety of biopsy in phaeochromocytoma and paraganglioma: an international, multicentre, retrospective cohort study.

Safety of biopsy in phaeochromocytoma and paraganglioma: an international, multicentre, retrospective cohort study.

Journal: The lancet. Diabetes & endocrinology

Published: November 13, 2025

In Vitro Model Employing Contrast-enhanced Ultrasound (CEUS) for the Simulation of Radiologic Intraoperative Liver Punctures and Biopsies.

In Vitro Model Employing Contrast-enhanced Ultrasound (CEUS) for the Simulation of Radiologic Intraoperative Liver Punctures and Biopsies.

Journal: RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin

Published: October 30, 2025

Combined Single-Session Stereotactic Biopsy and Microwave Ablation of Primary and Secondary Liver Tumors.

Combined Single-Session Stereotactic Biopsy and Microwave Ablation of Primary and Secondary Liver Tumors.

Journal: Biomedicines

Published: October 07, 2025

Contrast-enhanced ultrasound perfusion quantification of solid liver lesions: First intraoperative characterization of tumor microvascularization.

Contrast-enhanced ultrasound perfusion quantification of solid liver lesions: First intraoperative characterization of tumor microvascularization.

Journal: Clinical hemorheology and microcirculation

Published: September 18, 2025

Stereotactic two-needle irreversible electroporation of liver tumors near critical structures: a proof-of-concept study.

Stereotactic two-needle irreversible electroporation of liver tumors near critical structures: a proof-of-concept study.

Journal: European radiology experimental

Published: September 06, 2025

NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial.

NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial.

Journal: ESMO open

Published: August 13, 2025

Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial.

Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial.

Journal: ESMO open

Published: February 18, 2025

Showing 1-12 of 67

Last Updated: 09/26/2026